Stock NAMS NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NewAmsterdam Pharma Company N.V. Nasdaq

Equities

NAMS

NL00150012L7

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
19.29 USD -1.53% Intraday chart for NewAmsterdam Pharma Company N.V. -3.55% +72.69%
Jul. 08 NewAmsterdam Pharma Completes Enrollment for Phase 3 Trial of Potential Cardiovascular Disease Treatment MT
Jul. 08 NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. NAMS Stock
  5. News NewAmsterdam Pharma Company N.V.
  6. Press Releases